Omid Hamid

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6337848/publications.pdf

Version: 2024-02-01

64 papers	45,670 citations	57758 44 h-index	123424 61 g-index
64 all docs	64 docs citations	64 times ranked	39553 citing authors

#	Article	IF	Citations
1	Safety and Activity of Antiâ€“PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	27.0	6,820
2	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028.	27.0	5,183
3	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	27.0	4,838
4	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	27.8	4,342
5	Safety and Tumor Responses with Lambrolizumab (Antiâ€“PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
6	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	7.0	2,857
7	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1889-1894.	1.6	1,809
8	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
9	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	10.7	1,419
10	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine, 2016, 375, 1845-1855.	27.0	1,140
11	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq1 1 0.784314 rgBT /Ove	10.7	1,093
12	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, The, 2017, 390, 1853-1862.	13.7	1,032
13	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. New England Journal of Medicine, 2018, 379, 722-730.	27.0	983
14	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
15	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1239-1251.	10.7	812
16	Safety and Efficacy of Durvalumab (MEDI4736), an Antiâ€“Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3119-3125.	1.6	755
17	An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 2012, 61, 1019-1031.	4.2	703
18	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627

#	Article	IF	Citations
19	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research, 2009, 15, 5591-5598.	7.0	531
20	Atezolizumab, an Antiâ€"Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology, 2016, 34, 833-842.	1.6	517
21	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine, 2011, 9, 204.	4.4	500
22	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600â€"Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	1.6	430
23	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	27.0	376
24	Targeting cytotoxic Tâ€lymphocyte antigenâ€4 (CTLAâ€4). Cancer, 2007, 110, 2614-2627.	4.1	275
25	Overall Survival and Durable Responses in Patients With BRAF V600â€"Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2016, 34, 871-878.	1.6	266
26	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	7.0	222
27	Sunitinib Therapy for Melanoma Patients with KIT Mutations. Clinical Cancer Research, 2012, 18, 1457-1463.	7.0	197
28	Long-Term Outcomes in Patients With BRAF V600â€"Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2018, 36, 667-673.	1.6	196
29	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 2017, 86, 37-45.	2.8	183
30	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^{V600}-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	1.6	173
31	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
32	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	1.6	145
33	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. Current Oncology Reports, 2012, 14, 441-448.	4.0	138
34	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	2.8	132
35	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 5869-5878.	7.0	131
36	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. British Journal of Cancer, 2018, 119, 670-674.	6.4	114

#	Article	IF	Citations
37	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opinion on Biological Therapy, 2013, 13, 847-861.	3.1	110
38	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immunity, 2010, 10, 9.	3.2	89
39	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 2012, 61, 733-737.	4.2	84
40	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 2016, 67, 46-54.	2.8	77
41	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research, 2019, 25, 6061-6072.	7.0	58
42	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
43	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunology, Immunotherapy, 2017, 66, 1249-1264.	4.2	56
44	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. Frontiers in Oncology, 2014, 4, 110.	2.8	51
45	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	3.7	47
46	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research, 2020, 26, 4531-4541.	7.0	46
47	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. Journal of Clinical Oncology, 2016, 34, 9504-9504.	1.6	44
48	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	7.1	38
49	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clinical Cancer Research, 2022, 28, 71-83.	7.0	37
50	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. Journal of Clinical Oncology, 2018, 36, 9516-9516.	1.6	32
51	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical Cancer Research, 2020, 26, 4201-4205.	7.0	30
52	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.9	30
53	Improved survival in women versus men with merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 321-329.	1.2	26
54	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. Journal of Clinical Oncology, 2015, 33, 9063-9063.	1.6	23

#	Article	IF	Citations
55	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 312-320.	1.2	17
56	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
57	Optimal systemic therapy for high-risk resectable melanoma. Nature Reviews Clinical Oncology, 2022, 19, 431-439.	27.6	12
58	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25.	1.6	11
59	The association between facility volume and overall survival in patients with Merkel cell carcinoma. Journal of Surgical Oncology, 2020, 122, 254-262.	1.7	6
60	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumabâ€”Response. Clinical Cancer Research, 2020, 26, 2436-2436.	7.0	4
61	P865â€…Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
62	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.6	2
63	Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2017, 12, 1857-1858.	1.1	0
64	The â€œGreat Debateâ€•at Immunotherapy Bridge 2021, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, 179.	4.4	0